Kevan M Shokat Selected Research

TOR Serine-Threonine Kinases

1/2022	Tissue-restricted inhibition of mTOR using chemical genetics.
12/2012	Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
2/2012	The translational landscape of mTOR signalling steers cancer initiation and metastasis.
11/2010	Akt and autophagy cooperate to promote survival of drug-resistant glioma.
1/2010	New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
1/2009	EGFR signals to mTOR through PKC and independently of Akt in glioma.
10/2008	Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kevan M Shokat Research Topics

Disease

66	Neoplasms (Cancer) 03/2024 - 08/2002
9	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 04/2008
8	Glioma (Gliomas) 01/2017 - 12/2003
6	Breast Neoplasms (Breast Cancer) 12/2019 - 10/2008
5	Infections 01/2023 - 04/2013
5	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 10/2007
4	COVID-19 02/2021 - 01/2020
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 10/2009
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2018
2	Heart Diseases (Heart Disease) 01/2022 - 01/2018
2	Starvation 09/2021 - 02/2003
2	Genomic Instability 01/2019 - 07/2013
2	Carcinoma (Carcinomatosis) 01/2019 - 01/2016
2	Parkinson Disease (Parkinson's Disease) 10/2017 - 08/2013
2	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 12/2012
2	Triple Negative Breast Neoplasms 01/2017 - 01/2015
2	Hypersensitivity (Allergy) 01/2016 - 07/2012
2	Leukemia 08/2012 - 09/2008
2	Asthma (Bronchial Asthma) 06/2012 - 02/2010
2	Hepatocellular Carcinoma (Hepatoma) 09/2011 - 02/2011
2	Inflammation (Inflammations) 10/2008 - 08/2004
1	Adenocarcinoma 03/2024
1	Pathologic Processes 11/2023
1	Sjogren's Syndrome (Sjogren Syndrome) 01/2023
1	Human Influenza (Influenza) 01/2023
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022
1	Drug-Related Side Effects and Adverse Reactions 03/2021

Drug/Important Bio-Agent (IBA)

31	Phosphotransferases (Kinase)IBA 01/2020 - 08/2002
18	Proteins (Proteins, Gene)FDA Link 01/2023 - 04/2006
9	Sirolimus (Rapamycin)FDA Link 09/2021 - 09/2007
9	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2018 - 04/2008
7	TOR Serine-Threonine KinasesIBA 01/2022 - 10/2008
7	Protein Isoforms (Isoforms)IBA 01/2018 - 04/2008
6	Antiviral Agents (Antivirals)IBA 01/2023 - 03/2009
5	ErbB Receptors (EGF Receptor)IBA 01/2020 - 01/2007
5	Adenosine Triphosphate (ATP)IBA 12/2012 - 03/2007
5	PI103IBA 11/2010 - 05/2006
4	Guanosine Triphosphate (GTP)IBA 03/2024 - 12/2010
4	Transcription Factors (Transcription Factor)IBA 01/2023 - 08/2012
4	sapanisertibIBA 01/2020 - 02/2012
4	PP242IBA 01/2020 - 03/2010
3	Small Interfering RNA (siRNA)IBA 01/2023 - 02/2011
3	Messenger RNA (mRNA)IBA 01/2023 - 10/2020
3	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 10/2007
3	Mechanistic Target of Rapamycin Complex 1IBA 09/2021 - 12/2010
3	EnzymesIBA 01/2020 - 05/2006
3	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2018 - 12/2003
3	Carbonyl Reductase (NADPH)IBA 10/2017 - 02/2011
3	TensinsIBA 01/2017 - 11/2010
3	Dasatinib (BMS 354825)FDA Link 01/2016 - 01/2015
3	DNA (Deoxyribonucleic Acid)IBA 09/2014 - 04/2006
3	LipidsIBA 08/2014 - 01/2007
2	AntigensIBA 01/2023 - 12/2022
2	AndrogensIBA 01/2022 - 10/2007
2	oxidized low density lipoproteinIBA 01/2022 - 01/2018
2	Drug CombinationsIBA 01/2022 - 01/2018
2	Monomeric GTP-Binding ProteinsIBA 01/2022 - 11/2013
2	CholesterolIBA 01/2022 - 09/2011
2	Protein Kinases (Protein Kinase)IBA 01/2022 - 08/2002
2	MTOR InhibitorsIBA 01/2022 - 01/2018
2	RapaLink-1IBA 01/2022 - 01/2017
2	LDL Receptors (LDL Receptor)IBA 01/2022 - 01/2018
2	Oncogene Proteins (Oncogene Protein)IBA 01/2021 - 10/2009
2	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 12/2019 - 11/2015
2	LigandsIBA 11/2019 - 10/2013
2	Aurora Kinase AIBA 01/2018 - 04/2016
2	Proprotein Convertase 9IBA 01/2018 - 01/2018
2	LDL Lipoproteins (beta Lipoproteins)IBA 01/2018 - 01/2018
2	calcium-dependent protein kinaseIBA 12/2017 - 04/2013
2	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2017 - 02/2011
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2017 - 11/2010
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2017 - 11/2015
2	Mitogen-Activated Protein KinasesIBA 01/2017 - 01/2010
2	Biomarkers (Surrogate Marker)IBA 01/2015 - 05/2012
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2014 - 01/2009
2	epidermal growth factor receptor VIIIIBA 10/2013 - 05/2012
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 05/2012 - 09/2007
2	Tyrosine Kinase InhibitorsIBA 01/2010 - 01/2007
2	Imatinib Mesylate (Gleevec)FDA Link 10/2008 - 09/2008
1	sotorasibIBA 03/2024
1	Cysteine (L-Cysteine)FDA Link 03/2024
1	adagrasibIBA 03/2024
1	Aspartic Acid (Aspartate)FDA Link 03/2024
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 11/2023
1	Heterogeneous-Nuclear Ribonucleoproteins (Informatin)IBA 01/2023
1	Interleukin-6 (Interleukin 6)IBA 01/2023
1	Insulin-Like PeptidesIBA 01/2023
1	Janus KinasesIBA 01/2023
1	Tumor Suppressor Protein p53IBA 01/2023
1	Insulin ReceptorIBA 01/2023
1	Heterogeneous-Nuclear Ribonucleoprotein KIBA 01/2023
1	Carrier Proteins (Binding Protein)IBA 01/2023
1	AntibodiesIBA 12/2022
1	HaptensIBA 12/2022
1	Arginine (L-Arginine)FDA Link 01/2022
1	plitidepsin (aplidine)IBA 01/2021
1	Guanosine Diphosphate (GDP)IBA 10/2020

Therapy/Procedure

32	Therapeutics 01/2023 - 12/2003
3	Drug Therapy (Chemotherapy) 01/2016 - 04/2008
2	Radiotherapy 02/2015 - 04/2006